Location Directory

Clinical trials in Philadelphia, Pennsylvania

This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17113

Shown on this page

Current sort

Institutions in Philadelphia

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Ovarian Cancer, BRCA Mutation
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 25 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 3,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1240
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 813 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 604
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 426 more

Conditions: Cerebral Palsy
Interventions: APPLES-tele, Parent-centered Approach (PCA) Support Intervention, Standard of Care; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 4 Months to 13 Months
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Chronic Spinal Cord Injury
Interventions: NVG-291, Placebo; Drug
Lead sponsor: NervGen Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more

Conditions: Crohn's Disease, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 35
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more

Conditions: Type 2 Diabetes
Interventions: LY3457263, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more

Conditions: Depressive Disorder, Major
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Moorpark, California • Orange, California • New Haven, Connecticut + 29 more

Conditions: Asthma
Interventions: Fp/ABS, FP, ABS, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 12 Years and older
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 91
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more

Conditions: Corneal Ulcer
Interventions: Mesenchymal Stromal Cells, Control Solution; Biological · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Primary Mediastinal Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib, Everolimus, Samuraciclib, PH FDC SC, Palbociclib, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Duarte, California • Irvine, California • San Francisco, California + 9 more

Clinical trials in Philadelphia, Pennsylvania

Filter and sort this location

Institutions in Philadelphia

Live official records

Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer